3-(hydroxymethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone | 125064-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(hydroxymethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone
• 英文别名: 1,2-Dihydro-3-hydroxymethyl-2-methyl-1-oxo-4-phenylisoquinoline；3-hydroxymethyl-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinoline；3-(hydroxymethyl)-2-methyl-4-phenylisoquinolin-1-one
• CAS: 125064-54-2
• 化学式: C₁₇H₁₅NO₂
• 分子量: 265.312
• InChiKey: TVVFKLVDTOMAQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(hydroxymethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone 在 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 2.5h， 生成 1,2-dihydro-2-methyl-1-oxo-4-phenyl-1(2H)-isoquinolineacetonitrile
  参考文献：
  名称：

  Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine

  摘要：

  A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity. Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead la. Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyrido[3,4-b]pyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists. Among the compounds synthesized, N-[3,5-bis(trifluoromethyl)benzyl]7,8-dihydro-N, 7-dimethyl-8-oxo-5-(substituted phenyl)6-pyrido[3,4-b]pyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of [I-125]- BH-SP binding in human IM-9 cells) of 0.21-0.34 nM and ED(50) values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg. These compounds exhibited significantly potent activity upon oral administration with ED(50) values of 0.068-0.17 mg/kg. Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.

  DOI：

  10.1021/jm00016a014
• 作为产物：
  描述：

  1,2-dihydro-2-methyl-1-oxo-4-phenyl-3-isoquinolinecarboxylic acid 在 sodium tetrahydroborate 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 反应 0.25h， 生成 3-(hydroxymethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone
  参考文献：
  名称：

  Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine

  摘要：

  A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity. Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead la. Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyrido[3,4-b]pyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists. Among the compounds synthesized, N-[3,5-bis(trifluoromethyl)benzyl]7,8-dihydro-N, 7-dimethyl-8-oxo-5-(substituted phenyl)6-pyrido[3,4-b]pyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of [I-125]- BH-SP binding in human IM-9 cells) of 0.21-0.34 nM and ED(50) values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg. These compounds exhibited significantly potent activity upon oral administration with ED(50) values of 0.068-0.17 mg/kg. Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.

  DOI：

  10.1021/jm00016a014

文献信息

• Isoquinolinones
  申请人：May & Baker Limited

  公开号：US05004747A1

  公开（公告）日：1991-04-02

  Therapeutically useful isoquinolinone derivatives of the formula A--X--R.sup.3, wherein A represents a group of the formula: ##STR1## wherein R.sup.1 and R.sup.2 represents cycloalkyl, alkyl, alkenyl or alkynyl optionally substituted by halogen or cycloalkyl, or represents optionally substituted aryl or heteroaryl, R.sup.4 represents hydrogen, halogen, optionally substituted alkyl, alkenyl or alkynyl, optionally substituted aryl or heteroaryl, or a group R.sup.6 O-- wherein R.sup.6 represents alkyl, aryl or arylalkyl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula: --Y.sup.1 --CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5 wherein Y.sup.1 represents carbonyl, hydroxymethylene or --C(OR).sub.2 -- wherein R represents alkyl or the two R symbols together represent alkylene and R.sup.5 represents hydrogen or optionally substituted alkyl or R.sup.3 represents a lactol or lactone ring, and pharmaceutically acceptable salts thereof, processes for their preparation and compositions containing them are described.

  该专利描述了具有治疗用途的异喹啉酮衍生物，化学式为A--X--R.sup.3，其中A代表下列化学式的基团：##STR1## 其中R.sup.1和R.sup.2代表环烷基、烷基、烯基或炔基，可以选择地被卤素或环烷基取代，或者代表可以选择地被取代的芳基或杂环芳基，R.sup.4代表氢、卤素、可以选择地被取代的烷基、烯基或炔基、可以选择地被取代的芳基或杂环芳基，或者一个基团R.sup.6 O--，其中R.sup.6代表烷基、芳基或芳基烷基，X代表乙烯或乙烯基，R.sup.3代表下列化学式的基团：--Y.sup.1 --CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5 其中Y.sup.1代表酰基、羟甲基或--C(OR).sub.2--，其中R代表烷基或两个R符号一起代表亚烷基，R.sup.5代表氢或可以选择地被取代的烷基，或者R.sup.3代表内酯或内酯环，以及其药用盐，描述了它们的制备方法和含有它们的组合物。
• Condensed heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0585913A2

  公开（公告）日：1994-03-09

  Novel compound represented by the formula: wherein ring A may be substituted; ring B represents an optionally substituted benzene ring; either X or Y represents -NR¹- (R¹ represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group), -O- or -S-, the other representing -CO-, -CS- or -C(R²)R2a- (R² and R2a independently represent a hydrogen atom or an optionally substituted hydrocarbon group), or either X or Y represents -N=, the other representing =CR³- (R³ represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group , an optionally substituted amino group, a substituted hydroxyl group or a mercapto group substituted by an optionally substituted hydrocarbon group); ........ represents a single or double bond; when ........ is a single bond, Z represents -CR⁴- (R⁴ represents a hydrogen atom, hydroxyl group or an optionally substituted hydrocarbon group) or a nitrogen atom, or (ii) when ........ is a double bond, Z represents a carbon atom; D represents a C₁₋₃ alkylene group which may be substituted by an oxo group or a thioxo group, or D and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thioxo group; E represents -NR⁵- (R⁵ represents a hydrogen atom or an optionally substituted hydrocarbon group), -O- or -S(O)n- (n is 0,1 or 2), or R⁵ and Y, taken together, may form a 5- to 7- membered ring which may be substituted by an oxo group or a thioxo group; G represents a bond or a C₁₋₃ alkylene group; Ar represents an optionally substituted aryl group or an optionally substituted heterocyclic group, provided that (1) when (i) -X-Y- represents - O-CO- or -CO-O-, (ii) D represents -CO- and (iii) E represents -NR⁵-, either (a) G represents a C₁₋₃ alkylene group and Ar represents a substituted aryl group or a substituted heterocyclic group, or (b) G represents a bond and R⁵ represents an optionally substituted hydrocarbon group, and (2) when -X-Y- represents -NH-CO-, D represents -CO-, or a salt thereof having an excellent activity of inhibiting ACAT, lowering chlesterol in blood and inhibiting tachykinin recepter, or a salt thereof, their production and use.

  由式表示的新型化合物： 其中环 A 可被取代 环 B 代表任选取代的苯环； X或Y代表-NR¹-（R¹代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基）、-O-或-S-，另一个代表-CO-、-CS-或-C(R²)R2a-（R²和R2a独立地代表氢原子或任选取代的烃基）、或 X 或 Y 代表-N=，另一个代表 =CR³-（R³ 代表氢原子、卤素原子、任选取代的烃基、任选取代的氨基、取代的羟基或被任选取代的烃基取代的巯基）； ........ 代表单键或双键； 当 ........ 为单键时，Z 代表-CR⁴-（R⁴ 代表氢原子、羟基或任选取代的烃基）或氮原子；或 (ii) 当 ........ 为双键时，Z 代表碳原子； D 代表可被氧代基团或硫代基团取代的 C₁₋₃亚烷基，或 D 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 元环； E 代表-NR⁵-（R⁵ 代表氢原子或任选取代的烃基）、-O-或-S(O)n-（n 为 0、1 或 2），或 R⁵ 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 分子环； G 代表键或 C₁₋₃ 亚烷基； Ar 代表任选取代的芳基或任选取代的杂环基，条件是 (1) 当(i)-X-Y-代表-O-CO-或-CO-O-，(ii)D 代表-CO-和(iii)E 代表-NR⁵-时， (a) G 代表 C₁₋₃亚烷基，Ar 代表取代的芳基或取代的杂环基、(2) 当-X-Y-代表-NH-CO-时，D代表-CO-，或其盐具有抑制 ACAT、降低血液中胆固醇和抑制速激肽受体的优异活性，或其盐的生产和使用。
• Isochinolinone derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0634402A1

  公开（公告）日：1995-01-18

  Novel compounds represented by the formula: wherein the ring A and the ring B each stand for an optionally substituted benzene ring; Ar stands for an optionally substituted aryl group or an optionally substituted heterocyclic group; Q stands for an oxygen atom or a sulfur atom; R stands for a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group; X stands for -O- or -NR¹- wherein R¹ stands for a hydrogen atom or an optionally substituted hydrocarbon group; Y stands for -O-, -NR²- wherein R² stands for a hydrogen atom or an optionally substituted hydrocarbon group, or a bond; m denotes 1, 2 or 3, and n denotes 0, 1 or 2, and salts thereof which have an excellent calcium- or substance P receptor-antagonistic activity, being useful for treating a cerebralvascular disorder in mammals such as cerebralischemia, cerebral edema and neuronal damage, their production and use.

  式所代表的新型化合物： 其中环 A 和环 B 各代表一个任选取代的苯环； Ar 代表任选取代的芳基或任选取代的杂环基团； Q 代表氧原子或硫原子； R 代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基； X 代表-O-或-NR¹-，其中 R¹ 代表氢原子或任选取代的烃基； Y 代表-O-、-NR²-（其中 R² 代表氢原子或任选取代的烃基）或键； m 表示 1、2 或 3，以及 n 表示 0、1 或 2，及其盐类，它们具有优异的钙或 P 物质受体拮抗活性，可用于治疗哺乳动物的脑血管疾病，如脑缺血、脑水肿和神经元损伤。
• US5004747A
  申请人：——

  公开号：US5004747A

  公开（公告）日：1991-04-02
• US5482967A
  申请人：——

  公开号：US5482967A

  公开（公告）日：1996-01-09